Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer (NCT00031980) | Clinical Trial Compass
CompletedPhase 2
Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
United States30 participantsStarted 2002-03
Plain-language summary
RATIONALE: Cyclosporine may improve low blood counts caused by hematologic cancer.
PURPOSE: Phase II trial to study the effectiveness of cyclosporine in treating patients who have low blood counts caused by hematologic cancer.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Diagnosis of T-cell large granular lymphocytic leukemia
* Increased numbers of large granular lymphocytes in peripheral blood smears
* CD3+CD8+CD57+ immunophenotype by flow cytometry AND
* CD3+CD57+ cell count at least 2,000/mm\^3 OR
* CD3+CD57+ cell count at least 500/mm\^3 with clonal T-cell receptor beta gene rearrangement
* Patients must have at least 1 of the following:
* Severe neutropenia (absolute neutrophil count (ANC) less than 500/mm\^3)
* Neutropenia (ANC less than 1,000/mm\^3) and recurrent infections
* Anemia (hemoglobin less than 9 g/dL)
* Thrombocytopenia (platelet count less than 50,000/mm\^3)
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* NCI CTC 0-3
Hematopoietic:
* See Disease Characteristics
Hepatic:
* Bilirubin no greater than 2 times upper limit of normal (ULN)
Renal:
* Creatinine no greater than 2 times ULN
Other:
* Not pregnant or nursing
* Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Endocrine therapy:
* No concurrent hormonal therapy except steroids for adrenal failure or hormones for nondisease-related conditions (e.g., insulin for diabetes)
* No concurrent dexamethasone or other steroidal antiemetics
Other:
* No prior cyclosporine therapy for this leukemia